A 28-year-old woman with generalized tonic-clonic seizures has been seizure-free on phenytoin 300 mg/day for 2 years. She now plans pregnancy and visits the clinic for preconception counseling. She is concerned about teratogenic effects. What is the most appropriate next step in management?

Explanation

## Preconception Management in Women with Epilepsy **Key Point:** Women of childbearing age on antiepileptics require preconception counseling and drug optimization to balance seizure control with teratogenic risk. ### Drug Selection in Pregnancy | Antiepileptic | Teratogenic Risk | Fetal Hydantoin Syndrome | Recommendation | |---|---|---|---| | Phenytoin | High | Yes (cleft palate, cardiac defects, hypoplasia) | Avoid if possible | | Valproate | Very High | Fetal valproate syndrome (neural tube defects, developmental delay) | Contraindicated | | Levetiracetam | Low | No | Preferred choice | | Lamotrigine | Low–Moderate | No | Acceptable alternative | | Oxcarbazepine | Moderate | Possible (hyponatremia risk) | Acceptable | **High-Yield:** Levetiracetam is the antiepileptic with the lowest teratogenic potential and is the preferred agent for women planning pregnancy. It does not induce hepatic enzymes and has minimal protein binding. **Clinical Pearl:** Switching should occur *before* conception, not during pregnancy, to allow stabilization on the new drug and avoid breakthrough seizures in the critical first trimester. ### Management Algorithm ```mermaid flowchart TD A[Woman of childbearing age on AED]:::outcome --> B{Planning pregnancy?}:::decision B -->|Yes| C[Preconception counseling]:::action C --> D[Review current AED teratogenicity]:::action D --> E{High-risk drug?}:::decision E -->|Yes: phenytoin, valproate| F[Switch to levetiracetam or lamotrigine]:::action E -->|No: already on LEV/LTG| G[Continue current drug]:::action F --> H[Stabilize 4–6 weeks before conception]:::action G --> H H --> I[Folic acid 4–5 mg daily]:::action I --> J[Proceed with conception]:::outcome ``` **Mnemonic:** **LEAF** — Levetiracetam, Lamotrigine are Excellent for pregnancy; Avoid Phenytoin, Valproate. ### Why Levetiracetam? 1. **Minimal teratogenic data** — no established fetal syndrome. 2. **No hepatic enzyme induction** — does not affect oral contraceptive efficacy or other drug metabolism. 3. **Minimal protein binding** — less competition with bilirubin in the fetus. 4. **Stable pharmacokinetics** — does not require dose adjustment in pregnancy. **Warning:** Phenytoin causes fetal hydantoin syndrome in 10–30% of exposed pregnancies (cleft lip/palate, cardiac defects, hypoplasia of nails and distal phalanges, developmental delay). Valproate carries a 1–2% risk of neural tube defects and up to 30–40% risk of developmental delay — it is contraindicated. ### Additional Counseling Points - Seizure control is essential; uncontrolled seizures pose greater risk to the fetus than most antiepileptics. - Folic acid supplementation (4–5 mg daily) should be started before conception and continued throughout pregnancy. - Antiepileptic levels may drop in pregnancy due to increased volume of distribution and hepatic metabolism; monitoring is recommended. - Vitamin K supplementation in the third trimester may reduce neonatal hemorrhage risk (especially with enzyme-inducing drugs).